Ferring expands HEART program for cash-paying fertility patients
Ferring fertility program expanded
Ferring Pharmaceuticals has announced an expansion of its Helping Expand Access to Reproductive Therapy (HEART) program, a cost-savings plan for patients considering fertility treatments. Under the new plan, women who are prescribed urofollitropin for injection (Bravelle) and progesterone vaginal insert, 100 mg (Endometrin), will be eligible to receive the drugs at a discounted price. The program allows patients to receive five vials of Bravelle at no cost after they have purchased 15 or more vials of the hormone a $300 value, along with a free box of Endometrin (containing 21 inserts) a $100 value. To be eligible, patients must be cash-paying customers and must take the prescriptions to a participating pharmacy. More information can be found at
Pharmacists Play Unique Role in Advancing Health Equity for Patients With Chronic Disease
December 7th 2023A new study, outlined in a poster at ASHP Midyear 2023, identified 3 key themes associated with the ways in which pharmacists are positioned to advance health equity for patients with chronic diseases.
